ChromoTek anti-FGF-9 recombinant VHH, biotinylated
fgf9-b is a recombinant mono-biotinylated anti FGF9 Nanobody (VHH), suitable for ELISA, SPR, and BLI applications.
Cat no : fgf9-b
Synonyms
Validation Data Gallery
Product Information
fgf9-b is a recombinant mono-biotinylated anti FGF9 Nanobody (VHH), suitable for ELISA, SPR, and BLI applications.
Applications | BLI, SPR, ELISA |
Reactivity | Human |
Conjugate | Biotin |
Type | Nanobody |
Class | Recombinant |
Host | Alpaca |
Affinity | / |
Molecular Weight | 14.8 kDa |
Form | Liquid |
RRID | AB_3665411 |
Storage Buffer | 10 mM HEPES pH 7.0, 500 mM NaCl, 5 mM EDTA, 0.09% sodium azide |
Storage Condition | Store at -20°C |
Shipping | ambient |
Background | FGF-9 is a 26 kdA, glycosylated protein that is a member of the FGF superfamily. It primarily binds with FGFR3 and plays prominent roles in the regulating embryonic, lung, and skeletal development. It is a key regulator of male sex determination through promoting the proliferation of pre-Sertoli cells. It signals in conjunction with FGF-10 and SHH to drive the development of the lung mesenchymal space. FGF-9 is also a positive regulator of chondrocyte proliferation and osteogenesis during the bone formation process. Overexpression of loss of FGF-9 during skeletal development often results in aberrant bone growth. (PMID: 28395336, 25772309, 16540513, 25435023). |
Documentation
SDS |
---|
SDS_Immuno-Oncology VHHs (grouped) |